Related Experiment Video
Updated: May 12, 2026
An Orthotopic Resectional Mouse Model of Pancreatic Cancer
Published on: September 24, 2020
TL-118-anti-angiogenic treatment in pancreatic cancer: a case report
Shani Breuer1, Ofra Maimon, Liat Appelbaum
1Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel. shanibr@hadassah.org.il
Abstract:
Pancreatic cancer is one of the most aggressive malignant tumors. In recent years, little progress has been made in understanding and treatment of the disease. The two most commonly used chemotherapy drugs approved for the treatment of pancreatic cancer are gemcitabine and fluorouracil. Anti-angiogenic treatment is one of the current promising approaches in cancer translational research. Its aim is to inhibit development of new blood vessels and thereby prevent further tumor growth. We present a first description of a pancreatic cancer patient treated with standard chemotherapy and TL-118, an anti-angiogenic combination of 4 drugs that target non-overlapping aspects of the angiogenic process (Provided by Tiltan Pharma Ltd for compassionate use). Our patient, treated with standard chemotherapy combined with TL-118, was diagnosed about 16 months ago and is still considered progression free, while being treated with that combination. Moreover, when the treatment with TL-118 was stopped, there was a clear elevation of tumor marker which dropped again with the renewal of TL-118. This effect was not achieved by gemcitabine treatment alone. Recently, a phase II clinical trial of TL-118 for pancreatic cancer patients that have not yet been treated with chemotherapy was initiated. (Tiltan Pharma Ltd). The study objective is to evaluate the efficacy, safety, and tolerability of TL-118 in gemcitabine-treated metastatic pancreatic cancer patients. This report describes a new approach in treating pancreatic cancer, enabling patients to obtain a longer progression-free survival using this new anti-angiogenic drug combination, added on standard chemotherapy.
Insights
Pancreatic cancer patients may achieve longer progression-free survival with TL-118, an anti-angiogenic drug combination, when added to standard chemotherapy. This novel approach shows promise in treating this aggressive malignancy.
Area of Science:
- Oncology
- Translational Cancer Research
Background:
- Pancreatic cancer is highly aggressive with limited treatment advancements.
- Standard chemotherapy options include gemcitabine and fluorouracil.
- Anti-angiogenic therapy is a promising strategy to inhibit tumor vascularization.
Observation:
- A pancreatic cancer patient received standard chemotherapy combined with TL-118, an investigational anti-angiogenic drug combination.
- The patient remained progression-free for 16 months on this combined treatment.
- Discontinuation of TL-118 led to tumor marker elevation, which decreased upon its reintroduction.
Findings:
- The combination of TL-118 with standard chemotherapy demonstrated a positive effect on progression-free survival.
- TL-118 showed a notable impact on tumor markers, an effect not observed with gemcitabine alone.
- This case suggests TL-118's potential as an adjunct therapy in pancreatic cancer.
Implications:
- This approach may offer a new strategy for extending progression-free survival in pancreatic cancer patients.
- Further clinical evaluation of TL-118 in combination therapy is warranted.
- TL-118 represents a potential advancement in managing pancreatic cancer treatment resistance.
